Literature DB >> 20813318

Stereotactic radiosurgery for lung tumors.

Richard I Whyte1.   

Abstract

Lung cancer remains the most common cause of cancer-related deaths in the United States, and although surgery remains the standard treatment for early-stage tumors, stereotactic radiation is gaining an increasing role as an alternative form of therapy. Initially a form of treatment designed for neurosurgical applications, during the past decade stereotactic radiosurgery (SRS) has gone from a novel treatment for patients deemed to be prohibitive candidates for surgical resection to the point that there is now an international, randomized, multicenter trial to compare SRS to lobectomy in otherwise-healthy patients. This article reviews the history of SRS as applied to lung tumors, summarizes the currently available data on efficacy and toxicity, and describes some of the current controversial aspects of this treatment. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20813318     DOI: 10.1053/j.semtcvs.2010.04.001

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  4 in total

Review 1.  Trial Watch: Anticancer radioimmunotherapy.

Authors:  Erika Vacchelli; Ilio Vitale; Eric Tartour; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-03       Impact factor: 8.110

2.  Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients.

Authors:  Wenxi Yu; Zimei Liu; Lina Tang; Feng Lin; Yang Yao; Zan Shen
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

3.  Gamma Radiation-Induced Rib Necrosis and Stereotactic Radiosurgery Failure.

Authors:  James El Haddi; Christina R Layton; Ulugbek Negmadjanov; John Roberts
Journal:  Cureus       Date:  2021-04-05

4.  Stereotactic radiosurgery, a potential alternative treatment for pulmonary metastases from osteosarcoma.

Authors:  Wenxi Yu; Lina Tang; Feng Lin; Dake Li; Jun Wang; Yao Yang; Zan Shen
Journal:  Int J Oncol       Date:  2014-02-10       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.